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Background
The absence of detectable HIV resistance after treat-
ment failure may result from non-adherence, especially
for drugs such as ritonavir-boosted PIs (PI/r) for which
minimum adherence may be sufficient to achieve sup-
pression. This analysis aimed to investigate the associa-
tion between adherence, indicated by a detectable PI
plasma concentration, and development of PI resistance
in patients presenting with virological failure of a PI/r
regimen.
Methods
Patients were included if they had virologically failed a
PI/r, defined as a viral load (VL) >1000 copies/mL after
≥4 months continuous exposure to a PI/r and with a
plasma sample available within 1 month of the estimated
VL failure date. Samples were analysed for PI levels by a
validated reversed-phase HPLC method; an undetectable
PI level was defined as below the PI-specific lower limit
of detection. Genotypic sequencing was also carried out
retrospectively on the identified sample for those with no
previous PI failure and PI resistance was defined as the
presence of ≥1 major PI mutation (IAS-USA). Logistic
regression was used to assess risk factors for an undetect-
able PI level and for detection of PI resistance at VL fail-
ure using exact methods for small datasets.
Results
85 patients were included. PI/r regimens were started in
Sept 2002 (median) with VL failure occurring a median
time of 17 months later. At time of starting the PI/r
(baseline), 57% were ARV-naïve, median CD4 count was
217 cells/mm
3 and median VL was 4.8 log10copies/mL.
43 patients (51%) had an undetectable PI level at time
of VL failure and were similar to those with detectable
levels in terms of demographics, ARV history and pre-
vious VL failure. However, injecting drug use was asso-
ciated with a greater risk of undetectable PI level
(univariate odds ratio (OR) IDU vs. not: 3.7; 95% CI:
1.1-12.5; p=0.038).
44 (52%) of the 85 patients were successfully tested for
resistance and had no previous PI failure. Those with
undetectable PI levels were significantly less likely to
have PI resistance (0% of 24 patients, 95% CI: 0-14%)
than those with detectable levels (25% of 20, 95% CI: 9-
49%), exact median unbiased estimate of OR: 0.1;
p=0.029. Baseline VL, CD4 count, demographic and
ARV-related variables were not associated with PI resis-
tance due to limited power in this dataset.
Conclusions
Non-adherence to a PI/r regimen, as measured by an
undetectable PI level is linked to a lower rate of detec-
tion of PI resistance at time of VL failure.
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